Pegcetacoplan · Empaveli
Peptide
Evidence outlook
Approved: Paroxysmal Nocturnal Hemoglobinuria, Complement-Mediated Renal Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (5)
- C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis EMPAVELI ® is indicated for the treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), to reduce proteinuria and the loss of kidney function.
- C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis (additional indications)
- Treatment of paroxysmal nocturnal haemoglobinuria
- EMPAVELI (pegcetacoplan) is a complement inhibitor indicated for: • the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to, or are intolerant of, a C5 inhibitor. • the treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) to reduce proteinuria. EMPAVELI is only available through a controlled distribution program. Information about the EMPAVELI controlled distribution program is available at https://www.empaveli.ca/en/.
- Aspaveli is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. Aspaveli is indicated for the treatment of adult and adolescent patients aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in combination with a renin-angiotensin system (RAS) inhibitor, unless RAS inhibitor treatment is not tolerated or contraindicated.
Development in Chronic Kidney Disease stopped as a strategic decision by the sponsor. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03500549 NCT03500549 · Paroxysmal Nocturnal Hemoglobinuria The study was randomized and actively controlled, with 41 participants assigned to pegcetacoplan and 39 to eculizumab, but treatment was open-label rather than blinded. The primary hemoglobin endpoint favored pegcetacoplan by 3.84 g/dL (95% CI 2.33–5.34; p<0.0001), while the available record does not report a power calculation. Registry: NCT03500549 | 3 | Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP (Baseline and Week 16) 2019-11-14 | Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP (Baseline and Week 16): Pegcetacoplan to Pegcetacoplan 2.37 Grams per deciliter (g/dL) (Standard Error 0.363) | Eculizumab to Pegcetacoplan -1.47 Grams per deciliter (g/dL) (Standard Error 0.666) | Partial signal | link ↗ |
View 1 more trial
NCT04085601 NCT04085601 · Paroxysmal Nocturnal Hemoglobinuria PRINCE randomized 53 adults with paroxysmal nocturnal hemoglobinuria who had not received a complement inhibitor to pegcetacoplan or supportive care in a 2:1 ratio, without blinding. Its two primary endpoints at Week 26 were hemoglobin stabilization and the change in lactate dehydrogenase (LDH). Hemoglobin stayed stable in 85.7% of patients on pegcetacoplan and in none on supportive care, and LDH fell much more with pegcetacoplan (both p<0.0001), so both primary endpoints were met. Sources: the FDA label (EMPAVELI) and the CT.gov posted results. Registry: NCT04085601 | 3 | Number of Subjects Who Achieved Hemoglobin (Hb) Stabilization (From Baseline (Day 1) up to Week 26); Change From Baseline in Lactate Dehydrogenase (LDH) Concentration At Week 26 (Baseline (Day 1) and Week 26) 2021-06-23 | Two registered primaries at Week 26, pegcetacoplan (n=35) vs supportive care without complement inhibitors (n=18): hemoglobin stabilization 30 (85.7%) vs 0 (0%), difference 73% (95% CI 57% to 89%), p<0.0001; change in LDH LS mean -1870 vs -400 U/L, difference -1470 U/L (95% CI -2113 to -827), p<0.0001 (EMPAVELI label Table 8; CT.gov posted results). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2 (1)
What this study did
Competitive landscape
Other Complement C3 drugs
Pegcetacoplan ophthalmic, Cevolisiran, ARO-C3. Compare all 4 Complement C3 drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Complement-Mediated Renal Disease: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Pegcetacoplan (Empaveli): this drug | Approved | Peptide | Complement C3 | not yet graded | No reviewed efficacy summary in this indication | |
| Iptacopan (Fabhalta) | Approved | Small molecule | Complement Factor B | not yet graded | No reviewed efficacy summary in this indication | |
| Pegcetacoplan Ophthalmic (Syfovre) | Approved(overall) | Peptide | Complement C3, Complement C3 / C3b | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Cevolisiran | Phase 2(overall) | RNA / oligonucleotide | Complement C3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ARO-C3 | Phase 1/2 | RNA / oligonucleotide | Complement C3 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Empaveli (Pegcetacoplan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.